Genetic and epigenetic factors contribute to the onset of preeclampsia
Introduction
At the blastocyst stage, the human embryo is anchored into the uterine wall during the implantation process. From then on, a part of the extra-embryonic tissues invades the endometrium, which leads to the formation of a placenta. The placenta is a transient organ essential for maintaining pregnancy and ensuring embryonic and foetal growth. Indeed, this organ is crucial for adequately establishing an immunological tolerance to the embryo, similar to a hemi-allogenic graft, for the secretion of hormones, and for nutrients and gas exchanges. Placentation is a multi-step process where the maternal endometrium must first undergo a decidualization, characterized by structural and biochemical modifications. Then, interactions between the trophoblasts, which are the principal cell type of the placenta, and decidual components lead to implantation sensu stricto. Finally, trophoblastic cells invade the decidua and restructure the uterine vascular system to increase the vascular flow at the utero-placental interface. This ultimate human-specific step leads to the formation of a hemochorial placenta at the end of the first trimester. Alterations of any event in this sequence may lead to obstetrical complications for the mother and/or the foetus. The main placental diseases are preeclampsia (PE) and intra-uterine growth restriction (IUGR).
Clinically, PE associates maternal pregnancy-induced hypertension (>140/90 mmHg) with proteinuria (>0.3 g a day), and in the majority of cases, mild to severe oedema. This syndrome affects up to 10% of the pregnancies (Sibai et al., 1997, Witlin and Sibai, 1998, Cecil et al., 2004). It is the major cause of perinatal materno-foetal morbidity and remains the main cause of pregnancy-associated-mortality in industrialized countries (Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy, 2000). Indeed, this multisystemic disease can lead to severe clinical conditions, such as HELLP (Haemolysis, Elevated Liver enzymes and Low Platelets) when a haemolytic process is observed and more rarely to eclampsia, when generalised seizures appear. Both threaten the life of the mother. The only way to resolve the symptoms is the delivery of the placenta. Thus, extraction of the foetus before normal term is the classical treatment for PE, leading to iatrogenic prematurity. Furthermore, in over 25% of the cases, PE induces IUGR, a condition defined by a rupture of the foetal growth curve, leading generally to low weight newborns, according to a given cut-off (Battaglia, 1967, Breart et al., 1982, Seeds and Peng, 1998, Ergaz et al., 2005). Consequently, PE indirectly contributes to the risk of developing the metabolic syndrome (a condition associated with low weight at birth characterized by obesity, type II diabetes, and cardiovascular disease at adult age (Barker et al., 1989)). PE is a real medical challenge since women suffering PE typically develop clinical signs and symptoms from mid-gestation (after 20 weeks of pregnancy), when it is too late to efficiently treat and limit the disease. Although the disease appears late, it is now widely recognized that the physiopathological process starts as early as the end of the first trimester of pregnancy. In PE, a shallow trophoblastic invasion of the spiral uterine arteries leads to the maintenance of their contractile properties and to the increase of the vascular resistance (Gerretsen et al., 1981, Kaufmann et al., 2003, Fisher, 2004). This defective invasion triggers a cascade of events that eventually leads to the appearance of the clinical signs (Roberts and Lain, 2002, Redman and Sargent, 2005, Roberts and Gammill, 2005). Research about PE has been extensive during the last decade, but significant improvements in early prediction or diagnosis of the disorder are still awaited. Nevertheless several physiopathological pathways have been elucidated in PE, with the identification of master factors, such as sFlt-1 (soluble Fms-like tyrosine kinase 1, Maynard et al., 2003) and endoglin (Venkatesha et al., 2006), two proteins influencing angiogenesis and vasculogenesis, and STOX1 (Storkhead-box protein 1) a transcriptional factor that seems to genetically predispose to PE in Dutch families (van Dijk et al., 2005). However, PE aetiology remains poorly understood since the disease is heterogeneous, multi-factorial and widely differs in women according to specific risk factors (Duckitt and Harrington, 2005) (primiparity, age of the mother, smoking habits, previous hypertension, familial history of gravidic hypertension, etc.). This review provides an overview of the current theories and emerging perspectives in the field of elucidating the physiopathological process of PE, focusing in particular on putative epigenetic signatures characterizing the pathological placentas.
Section snippets
Placentation process
During implantation the undifferentiated mononuclear trophoblast cells reside in two different types of highly specialized chorionic villi, the floating villi that float in maternal blood and anchoring villi present within the uterine wall that attach the fetus to the mother (cf. Fig. 1). These highly proliferative, undifferentiated trophoblast cells follow two separate pathways of differentiation (Cross et al., 1994). In floating villi, they have the unique ability to fuse and form the
The onset of preeclampsia
PE is commonly considered as a two-stages disease (Roberts and Gammill, 2005). The first stage relates to a partial failure of early trophoblast invasion and remodelling of the spiral arteries. Consequently, the vascular flow is restricted in PE placentas, and the insufficient blood supply to the placenta causes hypoxia. Ultimately, ischemic lesions induced by the oxidative stress appear (Granger et al., 2002, Gupta et al., 2005). The second stage is the maternal syndrome, which is
Genetic causes of preeclampsia
The molecular processes that cause poor placentation are more controversial and uncertain. It seems acceptable to think that any molecular anomalies that reduce the invasive capacity of EVCT could trigger PE and that factors involved in maternal response to placental defects are fundamental. Thus, the possibility of a genetic predisposition to PE has been considered. Indeed, frequency and severity of the disease are substantially higher in women with pre-existing maternal hypertension,
Acknowledgements
STC is a PhD student receiving a fellowship from the French Ministry of Research. English corrections by Ilies Kamoun are greatly acknowledged.
References (100)
Recent advances in medicine for newborn infants
J. Pediatr.
(1967)- et al.
Control of MMP-9 expression at the maternal–fetal interface
J. Reprod. Immunol.
(2002) Fibrinolysis and thrombosis
Baillieres Best Pract. Res. Clin. Haematol.
(1999)- et al.
Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial
Lancet
(1999) - et al.
Matrix metalloproteinase-9 Gene -1562C/T polymorphism mitigates preeclampsia
Placenta
(2007) - et al.
Trophoblast pseudo-vasculogenesis: faking it with endothelial adhesion receptors
Curr. Opin. Cell Biol.
(1998) - et al.
Matrix metalloprotease-9, placental syncytiotrophoblast and the endothelial dysfunction of pre-eclampsia
Placenta
(2003) - et al.
Sperm exposure and development of preeclampsia
Am. J. Obstet. Gynecol.
(2003) - et al.
Intrauterine growth restriction-etiology and consequences: what do we know about the human situation and experimental animal models?
Reprod. Toxicol.
(2005) - et al.
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation
Blood
(1994)
Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
J. Biol. Chem.
Lipid peroxidation in pregnancy: new perspectives on preeclampsia
Am. J. Obstet. Gynecol.
Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in preeclampsia
Taiwan J. Obstet. Gynecol.
Physiological implications of the materno-fetal oxygen gradient in human early pregnancy
Reprod. Biomed. Online
Haplotypes of angiotensinogen in essential hypertension
Am. J. Hum. Genet.
Oxygen and placental villous development: origins of fetal hypoxia
Placenta
Proteases and their inhibitors are indicative in gestational disease
Eur. J. Obstet. Gynecol. Reprod. Biol.
DNA methylation differences associated with tumor tissues identified by genome scanning analysis
Genomics
Priming and remodelling of human placental bed spiral arteries during pregnancy—a review
Placenta
Metalloproteinases and their inhibitors in matrix remodeling
Trends Genet.
Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations
Am. J. Hum. Genet.
Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia
Am. J. Obstet. Gynecol.
Significance of secondary structure predictions on the reactive center loop region of serpins: a model for the folding of serpins into a metastable state
FEBS Lett.
Placental debris, oxidative stress and pre-eclampsia
Placenta
Preeclampsia and the systemic inflammatory response
Semin. Nephrol.
Recent insights into the pathogenesis of pre-eclampsia
Placenta
NK cells and human pregnancy—an inflammatory view
Trends Immunol.
Impaired growth and risk of fetal death: is the tenth percentile the appropriate standard?
Am. J. Obstet. Gynecol.
Enhancement of mitochondrial oxidative stress and up-regulation of antioxidant protein peroxiredoxin III/SP-22 in the mitochondria of human pre-eclamptic placentae
Placenta
Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group
Am. J. Obstet. Gynecol.
The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature
J. Biol. Chem.
Primipaternity and duration of exposure to sperm antigens as risk factors for pre-eclampsia
Int. J. Gynaecol. Obstet.
Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia
Lancet
Placental mitochondria as a source of oxidative stress in pre-eclampsia
Placenta
Oxygen regulates human cytotrophoblast differentiation and invasion: implications for endovascular invasion in normal pregnancy and in pre-eclampsia
J. Reprod. Immunol.
Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses
Genes Dev.
A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13
Hum. Mol. Genet.
The intrauterine and early postnatal origins of cardiovascular disease and chronic bronchitis
J. Epidemiol. Community Health
Human chorionic gonadotropin in human placentas from normal and preeclamptic pregnancies
Arch. Gynecol. Obstet.
Paracrine and autocrine regulators of trophoblast invasion—a review
Placenta
Risk of fetal growth retardation as a result of maternal hypertension. Preparation to a trial on antihypertensive drugs
Dev. Pharmacol. Ther.
Mucin and proteoglycan functions in embryo implantation
Bioessays
Cecil Textbook of Medicine
Searching for genetic clues to the causes of pre-eclampsia
Clin. Sci. (Lond.)
Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia
Hypertension
Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study
Am. J. Med. Genet. A
Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells
Mol. Hum. Reprod.
Hypoxia-inducible factors 1alpha and 2alpha regulate trophoblast differentiation
Mol. Cell. Biol.
Implantation and the placenta: key pieces of the development puzzle
Science
Cited by (100)
Exposure to endocrine disrupting chemicals impacts immunological and metabolic status of women during pregnancy
2023, Molecular and Cellular EndocrinologyMiR-141-3p downregulation promotes tube formation, migration, invasion and inhibits apoptosis in hypoxia-induced human umbilical vein endothelial cells by targeting Notch2
2021, Reproductive BiologyCitation Excerpt :The results suggested that silencing Notch2 counteracted the inhibitory effect of miR-141-3p inhibitor on the apoptosis of hypoxia-induced HUVECs. The pathogenesis of PE is attributed to multifarious elements including genetic factors, nutritional factors, immune dysfunction, ischemia and hypoxia in placental trophoblast cells, and endothelial cell injury [16–18]. The malfunction of trophoblast cells and endothelial cells plays important roles in the development of PE.
Genetic Factors in the Etiology of Preeclampsia/Eclampsia
2021, Chesley’s Hypertensive Disorders in PregnancyEpigenetics in diagnosis, prognosis and therapy: Therapies targeting the epigenome
2020, Epigenetics and Reproductive HealthHypoxia-induced microRNA-141 regulates trophoblast apoptosis, invasion, and vascularization by blocking CXCL12β/CXCR2/4 signal transduction
2019, Biomedicine and Pharmacotherapy